immunotherapy

Research in Review
Immune Checkpoint Inhibitors May Increase Response to CAR-T Therapy in ALL
05/19/2017
JCP Editors
Pembrolizumab improves response to chimeric antigen receptor (CAR) T-cell treatments in pediatric patients with B-cell relapsed acute lymphoblastic leukemia (ALL), according to research that will be presented at...
Pembrolizumab improves response to chimeric antigen receptor (CAR) T-cell treatments in pediatric patients with B-cell relapsed acute lymphoblastic leukemia (ALL), according to research that will be presented at...
...
05/19/2017
Journal of Clinical Pathways
Research in Review
PD-L1 Expression Associated With Radiation Resistance in Head and Neck Cancer
05/16/2017
JCP Editors
PD-L1 expression may be a biomarker of local failure in human papillomavirus (HPV)-negative head and neck squamous cell carcinoma following radiotherapy, according to research published in Clinical Cancer Research...
PD-L1 expression may be a biomarker of local failure in human papillomavirus (HPV)-negative head and neck squamous cell carcinoma following radiotherapy, according to research published in Clinical Cancer Research...
PD-L1...
05/16/2017
Journal of Clinical Pathways
Research in Review
PD-1 Expression in T Cells Aids Immunotherapy Strategies for NSCLC
05/12/2017
JCP Editors
Early activation of programmed cell death-1 (PD-1) in CD8 T-cells after immunotherapy treatment is crucial to antitumor response for patients with non-small cell lung cancer (NSCLC), according to research published...
Early activation of programmed cell death-1 (PD-1) in CD8 T-cells after immunotherapy treatment is crucial to antitumor response for patients with non-small cell lung cancer (NSCLC), according to research published...
Early...
05/12/2017
Journal of Clinical Pathways
Research in Review
Patients With NSCLC Treated With Immunotherapy Likely to Respond to Chemo
05/09/2017
JCP Editors
Patients with advanced non-small cell lung cancer (NSCLC) who undergo salvage chemotherapy are 30% more likely to achieve partial response if they have been treated with a PD-1/PD-L1 checkpoint inhibitor, according...
Patients with advanced non-small cell lung cancer (NSCLC) who undergo salvage chemotherapy are 30% more likely to achieve partial response if they have been treated with a PD-1/PD-L1 checkpoint inhibitor, according...
...
05/09/2017
Journal of Clinical Pathways
Research in Review
PD-1 Expression in T-Cells Aids Immunotherapy Strategies for NSCLC
05/01/2017
JCP Editors
Early activation of programmed cell death-1 (PD-1) in CD8 T-cells after immunotherapy treatment is crucial to anti-tumor response for patients with non-small cell lung cancer (NSCLC), according to research published...
Early activation of programmed cell death-1 (PD-1) in CD8 T-cells after immunotherapy treatment is crucial to anti-tumor response for patients with non-small cell lung cancer (NSCLC), according to research published...
Early...
05/01/2017
Journal of Clinical Pathways
Department
Off-Label Immunotherapy Prescriptions Common, Expensive
04/12/2017
JCP Editors
Many patients receive immunotherapy prescriptions for off-label treatment, potentially contributing to unnecessary health care expenditures.  ----- Related Content Cost-Effective Immunotherapy Treatments for...
Many patients receive immunotherapy prescriptions for off-label treatment, potentially contributing to unnecessary health care expenditures.  ----- Related Content Cost-Effective Immunotherapy Treatments for...
Many...
04/12/2017
Journal of Clinical Pathways
Research in Review
B-Cell ALL Disease Burden May Influence CAR T-Cell Therapy Impact on Survival
04/10/2017
JCP Editors
CD19-specific chimeric antigen receptor (CAR) T-cell therapy is more likely to be effective when given immediately after front-line therapy rather than after relapse in certain patients with B-cell acute...
CD19-specific chimeric antigen receptor (CAR) T-cell therapy is more likely to be effective when given immediately after front-line therapy rather than after relapse in certain patients with B-cell acute...
...
04/10/2017
Journal of Clinical Pathways
Research in Review
Maintenance Therapy for MCL Improved by Targeted Drugs
04/10/2017
JCP Editors
Recent advances in targeted therapies have the potential for major impacts on treatment practices for mantle cell lymphoma (MCL), according to a recent review published in Pharmaceuticals...
Recent advances in targeted therapies have the potential for major impacts on treatment practices for mantle cell lymphoma (MCL), according to a recent review published in Pharmaceuticals...
Recent...
04/10/2017
Journal of Clinical Pathways
Research in Review
Immune Systems Impact Immunotherapy Effectiveness in Head and Neck Cancer
04/05/2017
JCP Editors
Specific immune cells surrounding tumors may play a crucial role in how patients with head and neck cancer respond to nivolumab immunotherapy, according to research presented at the American Association of Cancer...
Specific immune cells surrounding tumors may play a crucial role in how patients with head and neck cancer respond to nivolumab immunotherapy, according to research presented at the American Association of Cancer...
...
04/05/2017
Journal of Clinical Pathways
Research in Review
Prior Antibiotics May Reduce Immunotherapy Efficacy in Patients With Cancer
02/14/2017
JCP Editors
Patients with cancer who receive antibiotics within a month before beginning their immunotherapy treatment may find the efficacy of their treatment reduced, according to a study that will be presented at the...
Patients with cancer who receive antibiotics within a month before beginning their immunotherapy treatment may find the efficacy of their treatment reduced, according to a study that will be presented at the...
...
02/14/2017
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
LLM Winter Symposium
February 7 ⁠–⁠ February 9
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
GD Solid Tumors
March 22 ⁠–⁠ March 23
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 4
WoundCon
May 1 ⁠–⁠ May 3
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use